significant shifts in serogroup predominance as shown in the Figure. Universal meningococcal C vaccination was introduced to the National Immunisation Program in 2003 and resulted in a 94% reduction in serogroup C disease by 2017. Serogroup B has been the dominant serogroup in Australia for two decades, although its incidence has declined naturally in recent years even before the availability of meningococcal B vaccines. 3 Since 2014, serogroups W and Y have caused increased cases of invasive disease.
Meningococcal vaccines and recommendations
There are currently two groups of meningococcal vaccines available in Australia:
• conjugate vaccines for protection against serogroups A, C, W and Y
• recombinant protein-based vaccines for protection against serogroup B.
Conjugate vaccines against serogroup C alone remain available as catch-up vaccines, e.g. NeisVac-C and Menitorix (the Hib-MenC vaccine). Polysaccharide vaccines are no longer supplied or recommended for use in Australia.
Introduction
Neisseria meningitidis is normally a commensal of the nasopharynx. However, it has the potential to invade the mucosa and cause invasive meningococcal disease, which most commonly presents as meningitis, septicaemia or both. There are 13 serogroups of N. meningitidis. Groups A, B, C, W 135 , Y and X cause the majority of disease.
1
Transmission occurs via large-droplet spread or direct contact with oral secretions. Carriage rates vary by population worldwide and by age. Asymptomatic carriage is most common in adolescents and young adults. 2 The incidence of invasive disease is highest in 0-4 year olds, especially infants, with a secondary peak in late adolescence and young adults. Invasive meningococcal disease is more common in Aboriginal and Torres Strait Islander children.
Risk factors
Risk factors for invasive disease include immune deficiencies such as asplenia, complement deficiencies and haemoglobinopathies, smoking, living in close quarters with other people, occupational exposure to N. meningitidis, and travel to highly endemic countries.
Incidence of disease
The incidence of invasive disease in Australia remains low, but has been increasing in recent years, with
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Meningococcal vaccines in Australia: a 2019 update contain capsular polysaccharide antigens conjugated to a protein carrier:
• Nimenrix -tetanus toxoid carrier
Indications and dosing schedules recommended by the Australian Technical Advisory Group on Immunisation vary by age and risk, 4 and are outlined in the Table. A single dose of Nimenrix is funded on the National Immunisation Program for babies aged 12 months. Since April 2019, year 10 students (aged 14-16 years) can receive the vaccine via a school-based program, with a catch-up dose available through general practice for 15-19 year olds who missed it at school. In recent years, individual states and territories have funded MenACWY vaccines for adolescents or provided them extensively, especially to high-risk age groups for control of outbreaks.
Nimenrix and Menveo induce a slightly better antibody level and persistence than Menactra in individuals over two years of age, 5, 6 and are the preferred brands above this age. 4 For those who require more than one dose for the primary course, it is preferable to use the same brand. However, if it is unavailable, an alternate ageappropriate brand can be used to complete the course.
Protective effectiveness of MenACWY vaccines may decline over time. An observational study in the USA showed that among adolescents, the effectiveness of Menactra in adolescents against all serogroups was highest in the first year after vaccination (79%), but decreased to 61% after 3-8 years. 7 Revaccination of adolescents is safe, but is not routinely recommended in Australia.
MenACWY vaccines are well tolerated and severe adverse events are rare. They can be co-administered with other routine vaccines in the National Immunisation Program with one exception -Menactra should not be co-administered with the pneumococcal vaccine Prevenar 13, as this may reduce the immune response to some pneumococcal serotypes. 8 If they are both used, plan to give Prevenar 13 first, followed by Menactra at least four weeks later if possible. If Menactra and Prevenar 13 are inadvertently co-administered, a dose of Prevenar 13 should be repeated after an interval of at least eight weeks. 
Recombinant meningococcal B (MenB) vaccines
Two recombinant protein-based multicomponent vaccines against serogroup B disease are currently available:
• Bexsero (also called MenB-MC) -contains multiple recombinant protein components and outer membrane vesicles of a strain of serogroup B meningococcus
• Trumenba -contains two subfamilies of factor-H binding protein (fHBP).
Indications and dosing schedules by age are summarised in the Table. MenB vaccines are currently not funded on the National Immunisation Program, but are available by private prescription. In South Australia, they are available through a state-based program.
Given the low incidence of meningococcal B disease, vaccine efficacy in pre-approval studies was inferred from immune responses to the component antigens, rather than from clinical end points.
Bexsero (MenB-MC) can be used from age six weeks, according to the Australian Immunisation Handbook. 4 A meta-analysis of immunogenicity studies found that 92% of children and adolescents achieved seroconversion 30 days after the primary vaccination course. However the long-term immunogenicity against some strains was suboptimal. 9 Early effectiveness data from the UK, where universal MenB-MC vaccination was introduced in 2015, showed that a two-dose primary regimen was 82.9% effective (95% confidence interval 24.1-95.2) against all strains of meningococcal B in infants, observed up to 10 months after vaccination. 10 The cost-effectiveness of universal MenB-MC vaccination is affected by the country-specific incidence of meningococcal B disease. 11 The incidence in Australia is relatively low compared to countries that adopted universal vaccination, at 0.47 cases per 100 000 in 2015. 3 Trumenba is registered for use from 10 years of age. Assessment of its clinical effectiveness is not yet available.
Bexsero and Trumenba are not interchangeable and the same brand must be used to complete the vaccination course. Bexsero contains four major antigens that are preserved across multiple species of Neisseria, and may provide some protection against other capsular groups. However the extent of clinically important cross-protection is not known.
12,13
MenB vaccines can be co-administered with MenACWY vaccines as well as other routine vaccinations. Fever is a very common adverse event following administration of Bexsero in young children and is more likely if Bexsero is co-administered with other vaccines. This risk can be reduced by separating administration of Bexsero from other vaccines (e.g. by at least three days). Prophylactic paracetamol is recommended for all children under two years receiving Bexsero in Australia. 4 
Conclusion
Safe and effective vaccines are available for prevention of invasive meningococcal disease caused by the most dominant serogroups in Australia. Primary care immunisation service providers are important for facilitating widespread uptake of meningococcal vaccines. MenACWY vaccine is provided for children aged 12 months and adolescents under the National Immunisation Program.
The MenACWY and MenB vaccines are strongly recommended for individuals at increased risk of invasive meningococcal disease. However, only the MenACWY vaccine is recommended for people travelling to regions where serogroups A, C, W, or Y are endemic. Health professionals should look out for at-risk patients and discuss vaccination options with them. Meningococcal vaccination is available for anyone who would like to reduce the risk of invasive meningococcal disease.
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